Subscribe
Share
Share
Embed
Opella adopts FMCG media tactics, The Giant Company launches GLP-1 store tours, Hinoki oil shows sleep promise, and longevity clinics charge up to $45,000.
Opella is tearing up pharma-style media strategy and replacing it with FMCG brand-building — and The Giant Company is redesigning its stores around GLP-1 drug users. If you sell supplements or functional food, both moves are a direct signal for where your category is heading.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: Plenty to dig into today.
Klara: We're looking at how consumer health brands are raiding the FMCG media playbook — and what that means for supplement marketers.
Marco: There's new sleep research on a Japanese tree oil that's worth paying attention to.
Klara: A US grocery chain is redesigning its stores around GLP-1 users.
Marco: And longevity clinics are going mainstream — at a price.
Klara: Let's get into it.
Marco: Consumer healthcare companies are ripping up their old media playbooks and replacing them with FMCG tactics — and every wellness brand in Europe should be paying attention.
Marco: For years, OTC health brands marketed themselves like miniature pharma companies. Clinical language. White coats. Functional claims. But consumer behaviour has shifted. People are making health decisions the same way they choose a moisturiser or a soft drink — through emotion, identity, and lifestyle fit.
Marco: Opella — the consumer health spin-off behind brands like Dulcolax and Allegra — is one of the clearest examples of this shift. They're consciously rebuilding their media strategy around FMCG brand-building principles. That means investing in channels where lifestyle and beauty brands already dominate: social, creator partnerships, culturally driven campaigns. The pressure is real. OTC and wellness brands are competing for the same eyeballs as skincare and food brands.
Klara: From a regulatory standpoint, this makes me cautious. EFSA rules — that's the European Food Safety Authority — are very strict about what health claims can actually appear in advertising. If brands start borrowing emotional, lifestyle-driven creative from beauty or fashion, they risk straying into claim territory that isn't authorised. Emotion is fine. But the moment you imply a product treats or prevents something without an approved claim behind it, you're in trouble.
Marco: That's a fair tension to flag. But I'd argue the brands getting this right aren't replacing clinical credibility — they're wrapping it in a warmer, more human story. Holland & Barrett has been doing this quietly for a couple of years now. The brands still stuck in white-coat mode are losing shelf presence and digital share.
Klara: The science has to travel with the story, not get left behind in the small print.
Marco: Now let's move to our next story.
Klara: A study just published suggests that the scent of a Japanese cypress tree oil could help people sleep through the night more effectively.
Klara: Sleep is one of the most competitive positioning spaces in European wellness right now. Brands are fighting hard for consumer attention across supplements, functional foods, and home wellness. But the ingredient conversation keeps circling back to the same three — magnesium, melatonin, ashwagandha. So when credible new data points to something different, it matters.
Klara: The research looked at Hinoki root essential oil — pressed from the Hinoki cypress tree, long used in Japanese wellness traditions. Participants who slept near its scent reported fewer nighttime awakenings and felt more alert in the morning. Critically, the researchers used brain-wave data to support those findings. That's more rigorous than a simple questionnaire — you're capturing neurological activity, not just asking people how they feel.
Klara: That said, I want to be honest about the limitations. We don't yet know the study size — and with sleep research, small sample groups are common. Before any brand starts making sleep claims around Hinoki oil, they need to understand that EFSA — the European Food Safety Authority — has a very specific authorisation process for health claims. No approved claim currently exists for this ingredient in Europe, as far as I'm aware. Brain-wave data is promising, but it's nowhere near the threshold EFSA requires.
Marco: Commercially, though, this is exactly the kind of early signal brands should be tracking. The Japanese wellness heritage angle is genuinely distinctive — it works beautifully for premium aromatherapy and home wellness positioning, where the story sells as much as the science. Brands don't need an EFSA claim to build cultural intrigue around an ingredient.
Klara: True — but the moment they imply it helps you sleep, the regulatory clock starts ticking.
Marco: Up next, our third story of the day.
Marco: A major US grocery chain has started running structured in-store tours specifically for customers using GLP-1 weight-loss medications like Wegovy and Ozempic.
Marco: GLP-1 drugs suppress appetite significantly. That changes how people shop, what portions they buy, and which nutrients they need to prioritise. Retailers who ignore that are leaving money on the table. The Giant Company, a sizeable US regional grocery chain, has decided to build a physical retail experience around this consumer segment rather than wait for the trend to mature.
Marco: The tours walk GLP-1 users through the store with guidance on food and supplement choices that match their changed nutritional needs — think high protein, micronutrient density, digestive support. This is one of the first times a major grocery retailer has moved from talking about the GLP-1 opportunity to actually restructuring the shopping journey around it.
Marco: For European supplement and functional food brands, this is a preview. European pharmacy chains and grocery retailers will get here. The brands that have already built GLP-1-adjacent positioning need to be knocking on buyers' doors right now — before the format decisions get made without them.
Klara: I'd add a note of caution on the supplement side. If brands start positioning products as essential companions to GLP-1 medication, they need to tread carefully. Any implied claim that a supplement addresses a drug's side effects or nutritional gaps would need solid evidence behind it. EFSA authorised claims for micronutrients exist, but they're ingredient-specific and context-specific. The science has to be clean.
Marco: Agreed — but the retailers setting up these tours aren't waiting for perfect science. They're responding to consumer demand. Brands that have the science and the ranging story ready will have a real advantage.
Klara: The window to get into that conversation is shorter than most brands think.
Marco: Let's move on to our fourth and final story.
Klara: Major nonprofit hospitals in the United States are now selling premium longevity programmes — and the ripple effects for European wellness brands will arrive sooner than most expect.
Klara: Longevity has been a supplement and wellness category buzzword for years. But it's largely been owned by biohackers, direct-to-consumer brands, and private clinics operating at the edges of mainstream medicine. That's changing fast.
Klara: Leading US hospital systems are opening dedicated longevity clinics with price tags ranging from five and a half thousand dollars to forty-five thousand dollars per programme. These aren't spa retreats. They combine advanced biomarker testing — meaning detailed blood and metabolic analysis — with personalised lifestyle, nutrition, and supplement recommendations. The crucial shift is institutional credibility. When a nonprofit hospital puts its name behind healthy ageing, mainstream consumers take notice in a way they never would with a wellness influencer.
Klara: From a science standpoint, this should raise the evidence bar significantly. These hospital programmes will presumably base their supplement recommendations on robust clinical data. Brands riding longevity positioning on thin evidence will look very exposed if a hospital recommends something different — or nothing at all.
Marco: Commercially, this is actually an enormous opportunity for the brands that have done their homework. Hospital longevity programmes become recommendation channels. If a brand's product has the clinical backing and the healthcare professional relationships already in place, it could end up in the hands of some of the highest-spending consumers in the category.
Klara: That's where we see things differently. I'd want brands to resist the temptation to rush into healthcare professional partnerships just to access this channel. The credibility only flows one way — if the science isn't solid, the association does more damage than good.
Marco: Europe's private longevity clinic sector is already growing. This US trend is probably eighteen months from becoming a mainstream retail challenge here. Brands that wait to see how it lands will be playing catch-up.
Marco: Today's through-line is clear — health consumers are spending more, expecting more, and reshaping every channel they touch, from grocery aisles to hospital corridors.
Klara: And every ingredient story, every format, every claim you make has to hold up under that scrutiny.
Marco: The bar just keeps rising.